**Question:** Long-term tamoxifen therapy may cause:

A. Increased risk of uterine cancer
B. Increased risk of thromboembolic events
C. Increased risk of breast cancer
D. Improved cardiovascular health

**Core Concept:** Tamoxifen is an antagonist/agonist of the estrogen receptor, primarily used as an adjuvant therapy for early-stage breast cancer to reduce the risk of recurrence and improve survival rates. Tamoxifen acts by blocking estrogen from binding to estrogen receptors, thereby reducing the growth of estrogen-sensitive tissues.

**Why the Correct Answer is Right:** Tamoxifen is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors in breast tissue, preventing estrogen from doing so and inhibiting the growth of estrogen-sensitive tumors. However, tamoxifen's effect on other estrogen-sensitive tissues is less predictable.

**Why Each Wrong Option is Incorrect:**

**A. Increased risk of uterine cancer:** Tamoxifen's action on the endometrium is complicated. While it reduces the risk of endometrial cancer by blocking estrogen-induced proliferation, it also increases the risk due to increased endometrial stimulation by its own estrogen-like activity (tamoxifen's active metabolite, endoxifen, binds to estrogen receptors in the endometrium).

**B. Increased risk of thromboembolic events:** Tamoxifen can increase the risk of thromboembolic events due to its antiplatelet activity (it inhibits platelet aggregation and reduces blood viscosity). However, this risk is generally considered low and outweighed by the benefits in breast cancer therapy.

**C. Increased risk of breast cancer:** Tamoxifen is contraindicated in patients with a history of breast cancer or increased breast cancer risk due to its estrogen-like activity (tamoxifen's active moiety, endoxifen, binds to estrogen receptors in the breast, causing a reduction in breast cancer risk).

**D. Improved cardiovascular health:** Tamoxifen is primarily prescribed for its antiestrogenic effects in breast cancer treatment, not its cardiovascular benefits.

**Why the Correct Answer is Right:**

Tamoxifen's primary indication is as an adjuvant therapy for early-stage breast cancer in women after surgery and radiation therapy. While tamoxifen can have some side effects, the primary benefit lies in its antiestrogenic action, which reduces the risk of breast cancer recurrence and improves survival rates.

**Why Each Wrong Option is Incorrect:**

**A. Increased risk of uterine cancer:** Tamoxifen reduces the risk of endometrial cancer by blocking estrogen-induced proliferation in breast cancer patients. However, the risk of endometrial cancer due to its estrogen-like activity (tamoxifen's active moiety, endoxifen, binds to estrogen receptors in the endometrium, leading to a reduction in endometrial cancer risk.)

**B. Increased risk of thromboembolic events:** While tamoxifen